JOHN FREDERICK DE GROOT to Thalidomide
This is a "connection" page, showing publications JOHN FREDERICK DE GROOT has written about Thalidomide.
Connection Strength
0.200
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.092
-
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
Score: 0.076
-
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov; 12(11):1167-72.
Score: 0.017
-
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
Score: 0.015